): For many years, an obstacle faced by tumor immunologists has been the failure of the immune system to respond to immune-enhancing therapeutic approaches in the setting of advanced disease. Recently, one explanation that has gained particular attention is whether antigen presented by a progressively expanding tumor cell population may result in the induction of T cell tolerance. Dr. Levitsky's laboratory has been pivotal in the development of tumor-cell based vaccines, and a major emphasis is being devoted to understand how factors mediating T cell activation versus tolerance may influence the efficacy of these strategies. In the last year, the applicants took advantage of the availability of T cell receptor (TCR) transgenic mice specific for a model tumor antigen expressed on a B cell lymphoma. Using this experimental model, they have recently shown that antigen specific CD4+ T cells are rendered tolerant during tumor progression. Moreover, these alterations in T cell function occur early in the course of the disease, suggesting that tolerance to tumor antigens may impose a significant barrier to immune-enhancing therapeutic approaches. Therefore, during the next four years it will be critical to understand the cellular and molecular basis of tumor-induced tolerance and more importantly, whether this state can be safely reverted. The knowledge to be gained in this endeavor is likely to shed light not only on the basic biology of host-tumor interactions but it also has significant clinical implications. As a medical oncologist, the applicant's ultimate goal will be to pursue the translation of these knowledge into the clinical arena where they may influence the design of the next generation of tumor immunotherapy strategies, aimed at safely breaking tolerance and potentially leading to the long elusive success of cancer immunotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08CA078656-01
Application #
2682201
Study Section
Subcommittee G - Education (NCI)
Program Officer
Springfield, Sanya A
Project Start
1998-09-07
Project End
1999-06-30
Budget Start
1998-09-07
Budget End
1999-06-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Villagra, Alejandro; Cheng, Fengdong; Wang, Hong-Wei et al. (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10:92-100
Cheng, Fengdong; Gabrilovich, Dmitry; Sotomayor, Eduardo M (2004) Immune tolerance in breast cancer. Breast Dis 20:93-103
Cuenca, Alex; Cheng, Fengdong; Wang, Hongwei et al. (2003) Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 63:9007-15
Cheng, Fengdong; Wang, Hong-Wei; Cuenca, Alex et al. (2003) A critical role for Stat3 signaling in immune tolerance. Immunity 19:425-36
Sotomayor, E M; Borrello, I; Rattis, F M et al. (2001) Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98:1070-7
Sotomayor, E M; Borrello, I; Tubb, E et al. (1999) In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 96:11476-81
Sotomayor, E M; Borrello, I; Tubb, E et al. (1999) Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5:780-7